BATS:HELX Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News $28.55 -1.41 (-4.71%) (As of 11/15/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsOwnershipRatings About Franklin Genomic Advancements ETF (BATS:HELX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HELX alerts:Sign Up Key Stats Today's Range$28.55▼$29.0650-Day Range$28.62▼$33.5152-Week Range N/AVolume3,069 shsAverage VolumeN/AMarket Capitalization$8.57 millionAssets Under Management$10.00 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF OverviewThe Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Franklin Genomic Advancements ETF ExpensesTypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.50%0.57%0.55%0.56%0.52%Other Expenses0.00%0.57%0.49%0.47%0.53%Total Expense0.50%0.73%0.71%0.69%0.71%Fee Waiver0.00%-0.74%-0.52%-0.36%-0.57%Net Expense0.50%0.60%0.61%0.64%0.59% Receive HELX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address HELX ETF News HeadlinesFranklin Emerging Markets UCITS ETF (FLXE)September 18, 2024 | investing.comFranklin Ethereum ETF (EZET)August 2, 2024 | finance.yahoo.comWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 17, 2024 | DTI (Ad)Chainlink Integration Enhances Transparency for 21Shares’ Ether ETFJuly 30, 2024 | msn.comFranklin Catholic Princ Em Sov Ucits Etf Share Price (CATHEM.MI)April 23, 2024 | lse.co.ukFranklin U.S. Treasury Bond ETFMarch 27, 2024 | money.usnews.comSee More Headlines HELX ETF - Frequently Asked Questions How have HELX shares performed this year? Franklin Genomic Advancements ETF's stock was trading at $30.47 at the beginning of the year. Since then, HELX shares have decreased by 6.3% and is now trading at $28.55. View the best growth stocks for 2024 here. How do I buy shares of Franklin Genomic Advancements ETF? Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Franklin Genomic Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Franklin Genomic Advancements ETF investors own include Merck & Co., Inc. (MRK), Abiomed (ABMD), Catalent (CTLT), iShares iBonds Dec 2025 Term Muni Bond ETF (IBMN), Net Element (NETE), Novavax (NVAX) and AbbVie (ABBV). Fund Details IssuerFranklin Templeton Investments Fund NameFranklin Genomic Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:HELX Inception Date2/25/2020 Fund ManagerMatthew J.Moberg, Joyce Lin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings66 Fund Statistics Assets Under Management$10.00 million Average Daily Volume$0.00 Discount/Premium-0.01% Administrator, Advisor and Custodian AdministratorFranklin Templeton Services, LLC AdvisorFranklin Advisers, Inc. CustodianState Street Bank and Trust Company DistributorFranklin Templeton Distributors, Inc. Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Miscellaneous Outstanding Shares300,000Beta1.00 Creation Unit50,000 Creation Fee$200.00 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Top 10 HELX HoldingsMedpace (NASDAQ:MEDP)Holding Weight: 5.91%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 5.79%Danaher (NYSE:DHR)Holding Weight: 5.27%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 5.00%Eli Lilly and Company (NYSE:LLY)Holding Weight: 4.97%Thermo Fisher Scientific (NYSE:TMO)Holding Weight: 4.96%Krystal Biotech (NASDAQ:KRYS)Holding Weight: 4.25%Natera (NASDAQ:NTRA)Holding Weight: 3.80%Samsung Biologics Co.,Ltd.Holding Weight: 3.80%AstraZeneca (NASDAQ:AZN)Holding Weight: 2.68%Full Holdings DetailsHELX Sector ExposureHELX Industry Exposure This page (BATS:HELX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
